NIH R01 · 2025
Pathogenesis of Immune checkpoint inhibitors-induced myocarditis
Project Summary Immune checkpoint inhibitors (ICIs) blocking PD-1, PD-L1, CTLA-4 and LAG-3 are groundbreaking therapies for cancer. Approximately 50% of cancer patients in the US are eligible for ICI therapy. However, ICI treatment can cause various immune-related adverse events (irAEs), which present as inflammation targeting numerous organs including the heart. ICI-associated myocarditis (ICI-myocarditis) occurs in 1-2% of patients treated with ICI therapy and is fatal in up to 50% of cases. More ICI inhibitors are in the testing phase and combining two or more ICI inhibitors has been shown to increase ICI-myocarditis incidence. Thus, there is an exceptionally high need to understand ICI…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.